Real-world outcomes in patients with brain metastases secondary to HR+/HER2− MBC treated with abemaciclib and local intracranial therapy
In this real-world study of patients diagnosed with brain metastases and initiating abemaciclib, most patients received radiation/local surgery to the brain before abemaciclib initiation. Although the outcomes in this real-world study are encouraging, it is unclear if the benefit was due to local therapy, abemaciclib, or the combination, and causality cannot be inferred. Further prospective clinical studies are needed to confirm the clinical benefit of this approach.
Authors
- Erika Yamazawa (ORCID: https://orcid.org/0000-0002-3079-2331)
- Priscilla Kaliopi Brastianos (ORCID: https://orcid.org/0000-0003-4470-8425)
- Wambui G. Gathirua‐Mwangi (ORCID: https://orcid.org/0000-0003-3688-2466)
- Kristin M. Sheffield (ORCID: https://orcid.org/0000-0003-3940-1795)
- Shen Zheng
- Sarah Rybowski
- Holly Martin (ORCID: https://orcid.org/0009-0008-8045-9298)
- Jincy John (ORCID: https://orcid.org/0009-0002-2215-8290)
- Dan He (ORCID: https://orcid.org/0009-0005-5596-1719)
Institutions
- Harvard University (US)
- Eli Lilly (United States) (US)
- Massachusetts General Hospital (US)
- Syneos Health (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/oncolo/oyae274
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Eli Lilly and Company